Aurora kinase modulators and method of use

US7776857B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Victor J. Cee · Thousand Oaks, US
• Holly L. Deak · Brookline, US
• Bingfan Du · Cambridge, US
• Stephanie Geuns-Meyer · Medford, US
• Brian L. Hodous · Cambridge, US
• Zihao Hua · Andover, US
• Matthew W. Martin · Arlington, US
• Isaac Marx · Somerville, US
• Hanh Nho Nguyen · North Palm Beach, US
• Philip R. Olivieri · Boston, US
• Kathleen Panter · Cambridge, US
• Karina Romero · Cambridge, US
• Laurie B. Schenkel · Somerville, US
• Ryan White · Thousand Oaks, US

Key dates

• Filing date: Apr 3, 2008
• Grant date: Aug 17, 2010
• Expiry date: Jul 1, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to chemical compounds having a general formula Iwherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.